BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 2491872)

  • 1. Role for the third constant domain of the IgG H chain in activation of complement in the presence of C1 inhibitor.
    Okada M; Utsumi S
    J Immunol; 1989 Jan; 142(1):195-201. PubMed ID: 2491872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of the first component of human complement, C1, by monoclonal antibodies directed against different domains of subcomponent C1q.
    Kilchherr E; Schumaker VN; Phillips ML; Curtiss LK
    J Immunol; 1986 Jul; 137(1):255-62. PubMed ID: 3486914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Co-operative interaction of subcomponents of the first component of complement with IgG: a functional defect of dimeric Facb from rabbit IgG.
    Okada M; Udaka K; Utsumi S
    Mol Immunol; 1985 Dec; 22(12):1399-406. PubMed ID: 3007976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody-independent C1 activation by E. coli.
    Tenner AJ; Ziccardi RJ; Cooper NR
    J Immunol; 1984 Aug; 133(2):886-91. PubMed ID: 6376630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of C1-mediated immune hemolysis by monomeric and dimeric peptides from the second constant domain of human immunoglobulin G.
    Lukas TJ; Muñoz H; Erickson BW
    J Immunol; 1981 Dec; 127(6):2555-60. PubMed ID: 7299136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. C1 dissociation. Spontaneous generation in human serum of a trimer complex containing C1 inactivator, activated C1r, and zymogen C1s.
    Laurell AB; Mårtensson U; Sjöholm AG
    J Immunol; 1987 Dec; 139(12):4145-51. PubMed ID: 2826582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The human complement C1 complex has a picomolar dissociation constant at room temperature.
    Tseng Y; Zavodszky P; Schumaker VN
    J Immunol; 1997 Jan; 158(2):937-44. PubMed ID: 8993014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody-independent activation of C1. II. Evidence for two classes of nonimmune activators of the classical pathway of complement.
    Peitsch MC; Kovacsovics TJ; Tschopp J; Isliker H
    J Immunol; 1987 Mar; 138(6):1871-6. PubMed ID: 3029223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effector functions of a mouse IgG that lacks the entire CH1 domain. C1q binding and complement fixation in the absence of antigen.
    Mizutani R; Igarashi T; Tanaka T; Shimada I; Arata Y
    J Immunol; 1993 Jan; 150(1):131-8. PubMed ID: 8417119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The relationship between the binding ability and the rate of activation of the complement component C1.
    Folkerd EJ; Gardner B; Hughes-Jones NC
    Immunology; 1980 Sep; 41(1):179-85. PubMed ID: 7429549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The influence of classical pathway components during alternative pathway--modulated immune complex aggregation: the role of C1 INH.
    Gronski P; Bodenbender L; Kanzy EJ; Seiler FR
    Behring Inst Mitt; 1984 Nov; (76):29-41. PubMed ID: 6335396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of C1 by soluble IgG aggregates as detected by a novel one-step hemolytic assay that specifically measures the proenzyme form of C1s.
    Doekes G; van Es LA; Daha MR
    J Immunol; 1983 Oct; 131(4):1924-9. PubMed ID: 6604753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surface-bound capsular polysaccharide of type Ia group B Streptococcus mediates C1 binding and activation of the classic complement pathway.
    Levy NJ; Kasper DL
    J Immunol; 1986 Jun; 136(11):4157-62. PubMed ID: 3517165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of C1q by monoclonal antibodies.
    Heinz HP; Loos M
    Behring Inst Mitt; 1984 Nov; (76):42-58. PubMed ID: 6335397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. C1 subcomponent complexes: basic and clinical aspects.
    Laurell AB; Sjöholm AG
    Behring Inst Mitt; 1993 Dec; (93):292-8. PubMed ID: 8172579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Control of C1 activation by nascent C3b and C4b: a mechanism of feedback inhibition.
    Ziccardi RJ
    J Immunol; 1986 May; 136(9):3378-83. PubMed ID: 3485688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The structure and function of immunoglobulin domains. IV. The distribution of some effector functions among the Cgamma2 and Cgamma3 homology regions of human immunoglobulin G1.
    Yasmeen D; Ellerson JR; Dorrington KJ; Painter RH
    J Immunol; 1976 Feb; 116(2):518-26. PubMed ID: 814165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The structure and function of immunoglobulin domains. II. The importance of interchain disulfide bonds and the possible role of molecular flexibility in the interaction between immunoglobulin G and complement.
    Isenman DE; Dorrington KJ; Painter RH
    J Immunol; 1975 Jun; 114(6):1726-9. PubMed ID: 1127227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Demonstration of the interaction of native C1 with monomeric immunoglobulins and C1 inhibitor.
    Ziccardi RJ
    J Immunol; 1985 Apr; 134(4):2559-63. PubMed ID: 3973388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Fc binding site for streptococcal protein G is in the C gamma 2-C gamma 3 interface region of IgG and is related to the sites that bind staphylococcal protein A and human rheumatoid factors.
    Stone GC; Sjöbring U; Björck L; Sjöquist J; Barber CV; Nardella FA
    J Immunol; 1989 Jul; 143(2):565-70. PubMed ID: 2738404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.